Skip to main content

Press releases | April 19, 2022

Fried Frank advised Centerview Partners, financial advisor to Checkmate Pharmaceuticals ("Checkmate"), in Checkmate's US$250 million acquisition by Regeneron Pharmaceuticals ("Regeneron") through a tender offer at an all-cash price of US$10.50 per share of Checkmate common stock.

Checkmate is a clinical-stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to combat cancer. Regeneron is an American biotechnology company. Through the acquisition, Regeneron will obtain Checkmate's leading investigational treatment known as vidutolimod, an advanced generation CpG-A oligodeoxynucleotide toll-like receptor 9 agonist delivered in a virus-like particle. The transaction is expected to close in mid-2022.

The Fried Frank team was led by corporate partner Roy Tannenbaum and included corporate partner Philip Richter and corporate associate Nate Goldfinger.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.